- Pure Extracts is working with Dr. Alexander MacGregor on development of mushroom products, including some combined with CBD.
- MacGregor is widely renowned as pharmaceutical science inventor, expert in pharmaceutical technology and novel drug-delivery systems.
- Pure Extracts is focused on expansion of its cannabis extraction business model to include mushroom formulations.
Pure Extracts Technologies (CSE: PULL) has established a key collaborative relationship with an expert in translating pharmaceutical knowledge into a sustainable business. The plant-based extraction company, which is focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is working closely with Dr. Alexander MacGregor on developing quality cannabis and mushroom formulations (https://cnw.fm/i9Tii).
Calling MacGregor a “key scientific advisor,” Pure Extracts announced that it is working with the pharmaceutical and biopharmaceutical expert on the development of CBD-infused mushroom wellness products as well as on researching psilocybin extraction methodologies. These efforts are focused on planning for Pure Extracts’ successful entrance into the psychedelic mushroom extraction space.
MacGregor serves as the dean of faculty, distinguished professor of biopharmaceutics and current president of the Toronto Institute of Pharmaceutical Technology (“TIPT”). TIPT is North America’s premier post-graduate institute of pharmaceutical sciences, technology and research. In addition, MacGregor is the CEO of TIPT’s parent company, Transpharm Canada Inc. Transpharm Canada has received a Health Canada Drug Establishment License, a Cannabis Drug License and a Dealer’s License issued under the Controlled Drugs and Substances Act (“CDSA”). Licensed to possess psychedelic drug compounds, Transpharm Canada has extensive expertise in conducting cannabis testing, clinical trials and drug development.
MacGregor is widely renowned as a pharmaceutical science inventor and an expert in pharmaceutical technology and novel drug-delivery systems; he is also the holder of several global patents in the field of medical treatments and pharmaceutical drug delivery technologies. His inventions have been key in the discovery of groundbreaking therapeutic drugs for the management of diabetes and the treatment of cancer, systemic infections and post-operative pain. MacGregor has served as a consultant to several multinational pharmaceutical companies, including GlaxoSmithKline, Valeant, Teva, Patheon, Sun Pharma and Beijing Double-Crane Pharma.
Pure Extracts is focused on the expansion of its business model to include mushroom formulations through the use of extraction processes that have proven compatible with its existing infrastructure (https://cnw.fm/lbdpj). The company is looking to leverage its expertise to develop high bio-available products and novel delivery methodologies including pills, capsules and edibles.
Pure Extracts is also eyeing the opportunity to become a significant extraction partner for the commercialization of new functional mushroom products. In fact, the company has already taken steps in that direction; the Company recently signed a letter of intent with PURICA(TM), one of Canada’s leading functional mushroom wellness brands, to partner together to produce CBD-enhanced mushroom products.
Headquartered in Pemberton, British Columbia, Pure Extracts is a plant-based extraction company that appears ideally positioned to be the dominant extraction company in the rapid development and commercialization of novel functional mushroom products.
For more information, visit the company’s website at www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://cnw.fm/PULL
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.